Free Pick from Jeff Brown: “Buy S.C.G .”
Jeff Brown picked Tesla in 2018 before it jumped 1,390%. He picked Nvidia before it jumped 3,545%. And he picked Bitcoin before it skyrocketed 22,750%.

And now he’s saying S.C.G. will be the next big tech play. He’s not the only one. Apple’s CEO even called it “the next big thing.”
Click here and get the name and ticker symbol!
Bruce N. Jacobs, insider at Kymera Therapeutics
Bruce N. Jacobs Insider Alerts

Get notified the next time Bruce N. Jacobs buys or sells Kymera Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Bruce N. Jacobs Insider Information

As CFO, Bruce directs financial operations and investor relations for Kymera Therapeutics. Bruce joined Kymera with more than 25 years of experience in health care financial services, investment banking and equity research. He previously was Managing Partner for Westfield Capital Management, a Boston-based equity investment firm. In addition to his core portfolio management responsibilities, he served on the firm’s Management Committee and as the Health Care Team Lead. Bruce was also a Director with Alex Brown & Sons/Deutsche Bank and part of the health care investment banking group and the equity research team. He graduated magna cum laude from the Wharton School of the University of Pennsylvania, earned a Master of Business Administration from the Harvard Business School and is a Chartered Financial Analyst. Bruce is currently a member of the Board of Directors at Boys & Girls Clubs of Boston and serves on the Board of Advisors for Life Science Cares.

What is Bruce N. Jacobs' net worth?

The estimated net worth of Bruce N. Jacobs is at least $69,925.70 as of March 15th, 2021. Mr. Jacobs owns 1,805 shares of Kymera Therapeutics stock worth more than $69,926 as of January 20th. This net worth estimate does not reflect any other investments that Mr. Jacobs may own. Learn More.

How do I contact Bruce N. Jacobs?

The corporate mailing address for Mr. Jacobs and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]

Has Bruce N. Jacobs been buying or selling shares of Kymera Therapeutics?

During the last quarter, Bruce N. Jacobs has sold $777,750.00 in shares of Kymera Therapeutics stock. Most recently, Bruce N. Jacobs sold 15,000 shares of the business's stock in a transaction on Wednesday, January 12th. The shares were sold at an average price of $51.85, for a transaction totalling $777,750.00.

Who are Kymera Therapeutics' active insiders?

Kymera Therapeutics' insider roster includes Bruce Booth (Director), Richard Chesworth (Insider), Bruce Jacobs (CFO), and Nello Mainolfi (CEO).

Are insiders buying or selling shares of Kymera Therapeutics?

In the last twelve months, Kymera Therapeutics insiders bought shares 1 times. They purchased a total of 544,166 shares worth more than $25,575,802.00. In the last twelve months, insiders at the sold shares 35 times. They sold a total of 915,246 shares worth more than $51,082,235.45. The most recent insider tranaction occured on January, 12th when CEO Nello Mainolfi sold 8,612 shares worth more than $448,512.96. Insiders at Kymera Therapeutics own 23.3 % of the company.

Information on this page was last updated on 1/12/2022.

Bruce N. Jacobs Insider Trading History at Kymera Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/12/2022Sell15,000$51.85$777,750.00View SEC Filing Icon  
12/3/2021Sell10,000$53.56$535,600.00View SEC Filing Icon  
9/3/2021Sell10,000$60.12$601,200.00View SEC Filing Icon  
3/15/2021Sell8,195$60.17$493,093.151,805View SEC Filing Icon  
3/11/2021Sell1,805$60.07$108,426.351,805View SEC Filing Icon  
3/8/2021Sell10,000$50.65$506,500.0010,000View SEC Filing Icon  
See Full Table

Bruce N. Jacobs Buying and Selling Activity at Kymera Therapeutics

This chart shows Bruce N Jacobs's buying and selling at Kymera Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kymera Therapeutics Company Overview

Kymera Therapeutics logo
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $38.74
Low: $38.53
High: $41.92

50 Day Range

MA: $55.91
Low: $38.74
High: $64.68

2 Week Range

Now: $38.74
Low: $29.93
High: $87.49

Volume

392,170 shs

Average Volume

428,118 shs

Market Capitalization

$1.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36
Free Pick from Jeff Brown: “Buy S.C.G .”
Jeff Brown picked Tesla in 2018 before it jumped 1,390%. He picked Nvidia before it jumped 3,545%. And he picked Bitcoin before it skyrocketed 22,750%.

And now he’s saying S.C.G. will be the next big tech play. He’s not the only one. Apple’s CEO even called it “the next big thing.”
Click here and get the name and ticker symbol!